Going Big

For the first half of this year, mergers and acquisitions among med-tech companies have been big, writes Stacy Lawrence at Fierce Medical Devices. The top five deals announced so far this year have been larger, she notes, that the top five from the first half of last year.

"Investors have taken well to these acquisitions; most have seen a double- or even triple-digit gain in their share prices since these med tech deals were announced," she says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.